 | Up a level |
Jain, Tania; Estrada-Merly, Noel; Salas, M Queralt; Kim, Soyoung; DeVos, Jakob D; Chen, Min; Fang, Xi; Kumar, Rajat; Andrade-Campos, Marcio; Elmariah, Hany; Agrawal, Vaibhav; Aljurf, Mahmoud; Bacher, Ulrike; Badar, Talha; Badawy, Sherif M; Ballen, Karen Kuhn; Beitinjaneh, Amer; Bhatt, Vijaya R; Bredeson, Christopher N; DeFilipp, Zachariah; ... (2024). Donor Types and Outcomes of Transplantation in Myelofibrosis: A CIBMTR Study. (In Press). Blood advances American Society of Hematology 10.1182/bloodadvances.2024013451
Pabst, Thomas; Papayannidis, Cristina; Demirkan, Fatih; Doronin, Vadim; Fogliatto, Laura M; Guttke, Christina; Gyan, Emmanuel; Hamad, Nada; Herrera, Pilar; Hultberg, Anna; Jacobs, Julie; Johnson, Amy J; Langlois, Angélique; Ma, Xuewen; Martinelli, Giovanni; Arnan, Montserrat; Müller, Rouven; Nottage, Kerri; Ofran, Yishai; Özcan, Muhit; ... (2023). Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study. The Lancet. Haematology, 10(11), e902-e912. Elsevier 10.1016/S2352-3026(23)00207-7
